NCT06712459View on ClinicalTrials.gov

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Transformed Splenic Marginal Zone Lymphoma
Trial Locations (7)

3000

Universitz Hospitals Leuven, Leuven

6500

Oncology Institute of Southern Switzerland, Bellinzona

10032

Columbia University, New York

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

75475

Hôpital Saint Louis, Paris

Unknown

University of Heidelberg, Heidelberg

BH7 7DW

University Hospitals Dorset, Bournemouth

All Listed Sponsors
lead

International Extranodal Lymphoma Study Group (IELSG)

OTHER

NCT06712459 - Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma | Biotech Hunter | Biotech Hunter